VFA
KIN

Virtus Fund Advisers’s Kindred Biosciences, Inc. KIN Stock Holding History

Virtus Fund Advisers’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-895
Closed -$17K – 2168
2014
Q2 		$17K Buy
+895
New +$15.2K ﹤0.01% 2546

Other funds holding KIN

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Virtus Fund Advisers's KIN Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Kindred Biosciences, Inc. (KIN) in Q3 2014, closing a stake of 895 shares — an estimated $17K sold.

Virtus Fund Advisers first reported a position in KIN in Q2 2014 and held it in 1 quarter. The position peaked at $17K in Q2 2014. 56 funds tracked by Wall St. Rank hold KIN as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Kindred Biosciences, Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 895 Kindred Biosciences, Inc. shares in Q3 2014, an estimated $17K.
  • Virtus Fund Advisers first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Kindred Biosciences, Inc. position peaked at $17K in Q2 2014.
  • 56 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.